Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease
Conditions
Interventions
Dexlansoprazole
Locations
33
United States
Childrens Center for Digestive Health Care, LLC
Mobile, Alabama, United States
University of Utah/ Primary Childrens Hospital
San Francisco, California, United States
Gastrointestinal Associates, PA
Centennial, Colorado, United States
Envision Clinical Research, LLC
Miami, Florida, United States
GI For Kids
Atlanta, Georgia, United States
Strada Patient Care Center, Department of Pediatric Gastroenterology
Chicago, Illinois, United States
Start Date
February 20, 2023
Primary Completion Date
October 31, 2027
Completion Date
October 31, 2027
Last Updated
January 14, 2026
NCT04506593
NCT07174882
NCT07344935
NCT07179250
NCT06916130
NCT01940185
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions